Case Report
BibTex RIS Cite

Diyabetik bir hastada her görme kaybı diyabete bağlı değildir: vaka sunumu, dev suprasellar kitle, menenjiom

Year 2020, Volume: 3 Issue: 1, 83 - 85, 15.01.2020
https://doi.org/10.32322/jhsm.460227

Abstract

Diyabet çağımızın salgın hastalığı olarak kabul
edilmekte ve tüm dünyada prevalansı hızla artmaktadır. Diyabet pek çok
hastalığın ve olumsuz durumun gelişmesinde yatkınlık oluşturmaktadır. Diyabetik retinopati orta ve ileri yaşta görme
azlığı yapan en önemli nedenlerdendir; gelişmiş ülkelerde 3’üncü körlük
nedenidir.
Ancak diyabetik retinopati dışında da yavaş gelişen görme kaybının birçok nedeni vardır. Yavaş
gelişen görme kayıpları en sık katarakt, göz kusurları, şeker hastalığı, yaşa
bağlı sarı nokta hastalığı gibi durumlara bağlıdır. Göz tansiyonunun ani
yükselmesi, göz enfeksiyonu gibi durumlar da ağrı ile birlikte kalıcı görme
kaybına yol açabilir. Birçok nörolojik
hastalıkta da görme ile ilgili yakınmalar ortaya çıkabilmektedir. Bunlar
arasında optik nörit, göz siniri damarının tıkanması, göz siniri tümörleri,
hipofiz bezi tümörleri, beyin damar tıkanıklıkları ve genetik hastalıklar gibi
nedenler vardır.
Endokrinoloji polikliniğimize
diyabet takibi için başvuran 5 yıldır tam görme kaybı olan ancak tetkiklerinde
dev suprasellar kitle tespit edilen ve sonrasında menenjiom tanısı koyduğumuz
olguyu sunuyoruz.

References

  • 1. Satman I, Yılmaz T, Şengül A, Salman S, Salman F, Uygur S. Population-basedstudy of diabetes and risk characteristics in Turkey: results of theTurkishdiabetesepidemiologystudy (TURDEP). Diabetes Care 2002; 25: 1551-6.
  • 2. Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009; 46: 85-95.
  • 3. Klein R, Lee KE, Knudtson MD, Gangnon RE, Klein BE. Changes in visual impairment prevalence by period of diagnosis of diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2009 Oct; 116: 1937-42. http://dx.doi.org/10.1016/j.ophtha.2009.03.012
  • 4. Vranic A, Popovic M, Cör A, Prestor B, Pizem J: Mitotic count, brain invasion and location are independent predictors of recurrence-free survival in primary atypical malignant meningiomas: A study of 86 cases. Neurosurgery 2010; 67: 1124-32.
  • 5. Nakasu S, Nakasu Y, Fukami T, Jito J, Nozaki K: Growth curve analysis of asymptomatic and symptomatic meningiomas. J Neurooncol 2011; 102: 303-10.
  • 6. Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH: Long-termexperinecewith World HealthOrganizationgrade III (malignant) meningiomas at a single institution. Int J Radiation Oncology Biol Phys 2010; 74: 427-32.
  • 7. Alexiou GA, Markoula S, Gogoy P, Kyritsis AP: Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 2010; 112: 261-7.
  • 8. Bădilă E, Weiss AE, Bartoş D, et al. Masseffect: a plethora of symptoms caused by an otherwise benign transitional pituitary meningioma. Case report, Rom J Morphol Embryol 2017; 58: 983-8.
  • 9. Hershenfeld SA, Sharpe JA. Monocular temporal hemianopia. Br J Ophthalmol 1993; 77: 424-7.
  • 10. Kwancharoen R, Blitz AM, Tavares F, Caturegli P, Gallia GL, Salvatori , Clinical features of sellar and suprasellar meningiomas. Pituitary 2014 Aug; 17: 342-8. doi: 10.1007/s11102-013-0507-z.
  • 11. Grisoli F, Vincentelli F, Raybaud C. Intrasellar meningioma. Surg Neurol 1983; 20: 36–41.
  • 12. Kinjo T, al-Mefty O, Ciric I. Diaphragma sellae meningiomas. Neurosurgery 1995; 36: 1082–92.
  • 13. Taylor S, Barakos JA, Harsh GR. 4th, Wilson CB magnetic resonance imaging of tuberculum sellae meningiomas. Preventing preoperative misdiagnosis as pituitary macroadenoma. Neurosurgery 1992;31: 621–7.

In a diabetic patient, each vision loss is not dependent on diabetes: case report, giant suprasellar mass, menengiomjiom

Year 2020, Volume: 3 Issue: 1, 83 - 85, 15.01.2020
https://doi.org/10.32322/jhsm.460227

Abstract

Diabetes is
considered an epidemic of our age and the prevalence of the
whole world is rapidly increasing.
Diabetes is predisposing to the development of many diseases and adverse
events. Diabetic retinopathy is the most important cause of blindness in middle
and advanced age; is the third cause of blindness in developed countries.
However, there are many reasons for slow vision loss other than diabetic
retinopathy. Slow-developing visual loss is most often due to cataracts, eye
defects, diabetes, age-related yellow spot disease. Sudden elevation of eye
pressure, such as eye infection, can also cause permanent visual loss with
pain. In many neurological diseases, complaints about vision can occur. These
include optic neuritis, blockage of the optic nerve, ocular neural tumors,
pituitary gland tumors, cerebral vascular occlusions and genetic diseases. We
present to our endocrinology outpatient clinic a case of complete loss of
vision for 5 years, but a giant suprasellar mass is detected in the examination
and a diagnosis of menengioma after that.

References

  • 1. Satman I, Yılmaz T, Şengül A, Salman S, Salman F, Uygur S. Population-basedstudy of diabetes and risk characteristics in Turkey: results of theTurkishdiabetesepidemiologystudy (TURDEP). Diabetes Care 2002; 25: 1551-6.
  • 2. Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009; 46: 85-95.
  • 3. Klein R, Lee KE, Knudtson MD, Gangnon RE, Klein BE. Changes in visual impairment prevalence by period of diagnosis of diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2009 Oct; 116: 1937-42. http://dx.doi.org/10.1016/j.ophtha.2009.03.012
  • 4. Vranic A, Popovic M, Cör A, Prestor B, Pizem J: Mitotic count, brain invasion and location are independent predictors of recurrence-free survival in primary atypical malignant meningiomas: A study of 86 cases. Neurosurgery 2010; 67: 1124-32.
  • 5. Nakasu S, Nakasu Y, Fukami T, Jito J, Nozaki K: Growth curve analysis of asymptomatic and symptomatic meningiomas. J Neurooncol 2011; 102: 303-10.
  • 6. Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH: Long-termexperinecewith World HealthOrganizationgrade III (malignant) meningiomas at a single institution. Int J Radiation Oncology Biol Phys 2010; 74: 427-32.
  • 7. Alexiou GA, Markoula S, Gogoy P, Kyritsis AP: Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 2010; 112: 261-7.
  • 8. Bădilă E, Weiss AE, Bartoş D, et al. Masseffect: a plethora of symptoms caused by an otherwise benign transitional pituitary meningioma. Case report, Rom J Morphol Embryol 2017; 58: 983-8.
  • 9. Hershenfeld SA, Sharpe JA. Monocular temporal hemianopia. Br J Ophthalmol 1993; 77: 424-7.
  • 10. Kwancharoen R, Blitz AM, Tavares F, Caturegli P, Gallia GL, Salvatori , Clinical features of sellar and suprasellar meningiomas. Pituitary 2014 Aug; 17: 342-8. doi: 10.1007/s11102-013-0507-z.
  • 11. Grisoli F, Vincentelli F, Raybaud C. Intrasellar meningioma. Surg Neurol 1983; 20: 36–41.
  • 12. Kinjo T, al-Mefty O, Ciric I. Diaphragma sellae meningiomas. Neurosurgery 1995; 36: 1082–92.
  • 13. Taylor S, Barakos JA, Harsh GR. 4th, Wilson CB magnetic resonance imaging of tuberculum sellae meningiomas. Preventing preoperative misdiagnosis as pituitary macroadenoma. Neurosurgery 1992;31: 621–7.
There are 13 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Case Report
Authors

Nazligül Karaüzüm Yalçın 0000-0001-8170-1631

Emine Kartal

Mustafa Utlu 0000-0002-6148-6644

Ahmet Veli Şanibaş

İdris Baydar This is me

Aykut Turhan 0000-0002-2535-9816

Elif Bayraktar

Yildirim Altun This is me

Ayşe Çarlıoğlu 0000-0002-5622-9563

Publication Date January 15, 2020
Published in Issue Year 2020 Volume: 3 Issue: 1

Cite

AMA Karaüzüm Yalçın N, Kartal E, Utlu M, Şanibaş AV, Baydar İ, Turhan A, Bayraktar E, Altun Y, Çarlıoğlu A. In a diabetic patient, each vision loss is not dependent on diabetes: case report, giant suprasellar mass, menengiomjiom. J Health Sci Med / JHSM. January 2020;3(1):83-85. doi:10.32322/jhsm.460227

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].

The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.